Cidara Therapeutics (CDTX) Misses Q2 EPS by 1c

Cidara Therapeutics (NASDAQ: CDTX) reported Q2 EPS of ($0.14), $0.01 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $7.61 million versus the consensus estimate of $11.55 million.

For earnings history and earnings-related data on Cidara Therapeutics (CDTX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$221 at BMO Capital
• Sharon AI surges premarket; New Oriental gains, Medline slips